Characteristics and Clinical Significance of Gene Mutation in Patients with Myelodysplastic Syndrome.
10.19746/j.cnki.issn.1009-2137.2021.06.029
- Author:
Fang ZHAO
1
,
2
;
Kai-Li WANG
1
,
2
;
Yu-Ting QIN
1
,
2
;
Tuerxun NILUPAR
1
,
2
;
Abulizi PATIGULI
1
,
2
;
Ming JIANG
1
,
2
;
Jian-Ping HAO
1
,
3
Author Information
1. Hematologic Disease Center, The First Affiliated Hospital of Xinjiang Medical University
2. Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi 830061, Xinjiang Uygur Autonomous Region, China.
3. Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi 830061, Xinjiang Uygur Autonomous Region, China,E-mail: 13579876416@163.com.
- Publication Type:Journal Article
- MeSH:
Genes, Regulator;
High-Throughput Nucleotide Sequencing;
Humans;
Mutation;
Myelodysplastic Syndromes/genetics*;
Prognosis
- From:
Journal of Experimental Hematology
2021;29(6):1864-1868
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the characteristics of gene mutations in patients with myelodysplastic syndromes (MDS) and its prognostic significance.
METHODS:High-throughput sequencing was used to detect 34 blood tumor-related genes in 210 patients with MDS, and the relationship with the revised International Prognostic Scoring System (IPSS-R) and the impact on prognosis of the patients were analyzed.
RESULTS:Among the 210 MDS patients, 142 cases (67.6%) showed mutations, and the first six genes with the highest mutation detection rate were ASXL1(20.5%), TET2(17.1%), U2AF1(14.3%), DNMT3A (11.9%), TP53(10.5%) and RUNX1(10.0%). The gene mutation rate of the patients in IPSS-R relatively high-risk group was higher than those in relatively low-risk group (P=0.001). Both TP53 and BCOR genes showed higher mutation rates in the higher risk group than in the lower risk group (P<0.05). Survival time of the patients in TP53 mutant group was lower than those in non-mutant group (P<0.001), survival time of patients in SF3B1 mutant group was higher than those in non-mutant group (P=0.018). According to the number of gene mutations, the patients could be divided into groups with 0-1, 2 and ≥3 gene mutations, and the median OS of the three groups were not reached, 43 and 27 months, respectively (P=0.004). The Multivariate analysis showed that the increasing number of gene mutations and TP53 mutation was the independent risk factors affecting prognosis of the patients, while SF3B1 mutation was the independent protective factor for the prognosis of the patients.
CONCLUSION:The gene mutation rate was higher in MDS patients. And the increasing numbers of gene mutation, TP53 and SF3B1 were the influence factors of prognosis in the patients.
